Thorough QT/QTc Evaluation of the Cardiac Safety of Secnidazole at Therapeutic and Supratherapeutic Doses in Healthy Individuals

SYM‐1219, a novel oral granule formulation of secnidazole, is under development as single‐dose treatment for bacterial vaginosis. This 4‐way, randomized, crossover study evaluated the effects of SYM‐1219 on electrocardiographic (ECG) parameters in 52 healthy subjects. Subjects were administered sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Darpo, Borje, Xue, Hongqi, Adetoro, Nikki, Matthews, Barbara G., Pentikis, Helen S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Drug Development
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836856/
https://www.ncbi.nlm.nih.gov/pubmed/28967984
http://dx.doi.org/10.1002/jcph.1014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836856/
https://www.ncbi.nlm.nih.gov/pubmed/28967984
http://dx.doi.org/10.1002/jcph.1014

Ejemplares similares